Lecithin cholesterol acyltransferase deficiency
Drug research and approvals for lecithin cholesterol acyltransferase deficiency: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 2 studies of lecithin cholesterol acyltransferase deficiency are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 2
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and…NCT07629999 · Phase 1 · Bristol-Myers Squibb · starts Jul 13, 2026
- LCAT (Lecithin Cholesterol Acyl Transferase) Natural History StudyNCT06217588 · Not reported · University of Pennsylvania · starts Aug 12, 2022
Phase 1 or earlier 12 of 18
- LisinoprilAngiotensin-converting enzyme inhibitor
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- BenazeprilAngiotensin-converting enzyme inhibitor
- EtodolacCyclooxygenase-2 inhibitor
- IndomethacinCyclooxygenase inhibitor
- LamotrigineSodium channel alpha subunit blocker
- MetoprololBeta-1 adrenergic receptor antagonist
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- RisperidoneSerotonin 2a (5-HT2a) receptor antagonist
- DesloratadineHistamine H1 receptor antagonist
- LevocetirizineHistamine H1 receptor antagonist
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA